Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as a 10 mCi (370 MBq) sterile solution for injection use. It is employed for myocardial perfusion imaging to assess coronary artery disease in adult patients.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Myoview (tetrofosmin) is used in cardiac imaging to evaluate myocardial blood flow.

Myocardial perfusion imaging: provides quantitative assessment of regional blood flow at rest and stress. Coronary artery disease assessment: helps identify ischemic territories and severity of disease. Stress and rest cardiac SPECT imaging: enables visualization of perfusion defects during pharmacologic or exercise stress.

Adverse reactions may occur following administration of Myoview.

Common Side Effects: - Nausea: mild, transient feeling of stomach upset. - Headache: mild to moderate intensity, usually resolves spontaneously. - Injection site pain: brief discomfort at the venipuncture site. - Flushing: transient warmth and reddening of the skin. - Dizziness: temporary light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure, potentially symptomatic. - Cardiac arrhythmia: abnormal heart rhythm that may need monitoring. - Myocardial infarction: rare occurrence of heart attack post‑administration. - Radiation‑induced injury: unlikely but possible tissue effects from radiotracer exposure.

Prior to using Myoview, consider the following safety measures.

Pregnancy: Category C; use only if potential benefits justify the potential risk to the fetus. Breastfeeding: discontinue nursing or discontinue the drug, as radiotracer may be excreted in milk. Renal impairment: monitor patients with reduced kidney function, as clearance may be altered. Thyroid disorders: avoid in patients with uncontrolled hyperthyroidism due to iodine uptake concerns. Concurrent radiopharmaceuticals: do not administer other technetium‑99m agents within 24 hours to prevent interference. Store at ambient temperature below 25°C: keep in the original shielded container, protect from light and moisture.

Myoview may interact with other agents that affect imaging quality or hemodynamics.

Major Interactions (Avoid): - Other technetium‑99m labeled agents: competitive binding may reduce image quality. - Iodine‑containing contrast media: can interfere with tracer distribution and interpretation. - Beta‑blockers: may blunt heart rate response during stress testing.

Moderate Interactions (Monitor Closely): - Caffeine‑containing products: may diminish stress test sensitivity. - Certain antihypertensives: may alter hemodynamic response and affect perfusion results.